Oct 30, 6:50 AM ET
Regeneron Pharmaceuticals reported third quarter 2026 total revenues of $5.1 billion, an increase of 36% compared to the same period in 2025. GAAP net income per diluted share rose 35% to $18.45, while non-GAAP diluted EPS grew 70% to $20.07, driven by strong commercial execution and increased Sanofi collaboration revenue.
- Total revenues for Q3 2026 increased 36% to $5.1 billion compared to Q3 2025.
- GAAP diluted EPS increased 35% to $18.45, and non-GAAP diluted EPS increased 70% to $20.07.
- EYLEA HD U.S. net sales grew 62% to $699 million, and global Libtayo net sales rose 51% to $550 million.
- Expanded collaboration with Sanofi adding next-generation antibodies, providing a $1.0 billion up-front payment.
Read the filing on SEC.gov ↗
Oct 6, 7:51 AM ET
Regeneron and Sanofi amended their antibody collaboration on October 1, 2026, to co-develop and co-commercialize four new long-acting antibodies. Sanofi will pay Regeneron a $1.0 billion upfront payment, with up to $7.0 billion more in milestones, and the two companies will share global profits equally. Regeneron also expects a third-quarter 2026 acquired IPR&D charge of about $22 million, or $0.18 per diluted share, and agreed to dismiss a lawsuit against Sanofi.
- Sanofi will pay Regeneron a $1.0 billion upfront payment under the Sixth Amendment dated October 1, 2026.
- Regeneron is eligible for up to an additional $7.0 billion in development, regulatory, and commercial milestone payments.
- Regeneron expects a third-quarter 2026 acquired IPR&D charge of about $22 million pre-tax, reducing GAAP and non-GAAP EPS by about $0.18 per diluted share.
- Regeneron agreed to dismiss its lawsuit over Sanofi's obligations to provide information on Dupixent commercialization and audit rights.
Read the filing on SEC.gov ↗
Sep 30, 4:14 PM ET
Regeneron's Compensation Committee granted CEO Leonard Schleifer and CSO George Yancopoulos one-time performance share units effective September 24, 2026, replacing their annual equity awards through 2036. Payouts depend on new product filings, approvals and revenue from new products over a performance period ending December 31, 2035, with a maximum of 2,700,000 PSUs for the CEO and 2,900,000 for the CSO. The filing also discloses that both executives received equity stakes in a newly formed, majority-owned subsidiary that the company says has nominal value and no significant assets.
- Grant effective September 24, 2026; performance period runs January 1, 2026 through December 31, 2035
- Revenue-based earnout starts at $10 billion of new product annual revenues and the maximum requires about $30 billion
- Award caps are 2,700,000 PSUs for the CEO and 2,900,000 PSUs for the CSO; shares are subject to a holding period until February 2036
- Both executives received stakes in a new subsidiary formed to explore a non-core business that has not yet commenced operations
Read the filing on SEC.gov ↗
Jul 30, 6:48 AM ET
Regeneron reported second quarter 2026 total revenues of $4.3 billion, up 17% from a year earlier, with non-GAAP diluted EPS up 11% to $14.29. GAAP net income fell 7% to $1.3 billion and GAAP diluted EPS fell 5% to $12.23, which the company said included a $1.02 per share negative impact from acquired in-process R&D. The company also narrowed or changed several 2026 guidance items, and it fully repaid the Sanofi Development Balance by the end of the quarter.
- Total revenues $4.3 billion, up 17%; Dupixent global net sales recorded by Sanofi rose 38% to $6.0 billion
- GAAP net income $1.3 billion, down 7%; non-GAAP net income $1.5 billion, up 8%
- 2026 guidance updated: GAAP gross margin on net product sales now 78%–79% (prior 77%–78%); capital expenditures now $1.030–$1.100 billion (prior $1.100–$1.200 billion)
- Company repurchased $1.2 billion of common stock in the quarter and had $2.5 billion remaining under its repurchase programs as of June 30, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.